Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After peaking at $341 in July, the stock plunged by over 25% to the current ...

Explore Amgen stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for AMGN.

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, ...

Amgen's stock price has shown a consistent upward trend, ... The recent stock price surge supports the key reversal candle at $210.01 in June 2023, fuelling the upward price momentum.

Amgen Inc. (NASDAQ: AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street’s reaction to the company’s latest data announcement regarding MariTide, ...

Amgen stock soared as much as 16% on Friday after it reported first-quarter earnings. The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug could be ...

But Amgen's top-selling drug of last year, Enbrel, saw its sales decline by 10% in 2023 to $3.7 billion, with the company blaming lower selling prices and inventory levels for the drop in revenue.

The Thousand Oaks, Calif.-based company reported first-quarter results on Thursday, including an update on its weight loss drug in development, which led analysts to update their Amgen stock price ...